A randomized clinical trial conducted by scientists from America demonstrated that the time required to resolve a sickle cell crisis showed no significant difference between groups receiving intravenous arginine and the control group receiving placebo.
Furthermore, this treatment did not affect either the amount of opioid medication used or the level of pain during the onset of crises.
The results of this scientific investigation were officially published in The Journal of the American Medical Association.
